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Abstract
Background Huntington’s Disease (HD) is a hereditary neurodegenerative disorder which affects individuals’ ability to walk, 
talk, think, and reason. Onset is usually in the forties, there are no therapies currently available that alter disease course, and 
life expectancy is 10–20 years from diagnosis. The gene causing HD is fully penetrant, with a 50% probability of passing the 
disease to offspring. Although the impacts of HD are substantial, there has been little report of the quality of life of people 
with the condition in a manner that can be used in economic evaluations of treatments for HD. Health state utility values 
(HSUVs), used to calculate quality-adjusted life-years (QALYs), are the metric commonly used to inform such healthcare 
policy decision-making.
Objectives The aim was to report HSUVs for HD, with specific objectives to use European data to: (i) describe HSUVs by 
demographic and clinical characteristics; (ii) compare HSUVs of people with HD in the UK with population norms; (iii) 
identify the relative strength of demographic and clinical characteristics in predicting HSUVs.
Methods European Huntington’s Disease Network REGISTRY study data were used for analysis. This is a multi-centre, 
multi-national, observational, longitudinal study, which collects six-monthly demographic, clinical, and patient-reported 
outcome measures, including the SF-36. SF-36 scores were converted to SF-6D HSUVs and described by demographic 
and clinical characteristics. HSUVs from people with HD in the UK were compared with population norms. Regression 
analysis was used to estimate the relative strength of age, gender, time since diagnosis, and disease severity (according to 
the Total Function Capacity (TFC) score, and the UHDRS’s Motor score, Behavioural score, and Cognition score) in pre-
dicting HSUVs.
Results 11,328 questionnaires were completed by 5560 respondents with HD in 12 European countries. Women generally 
had lower HSUVs than men, and HSUVs were consistently lower than population norms for those with HD in the UK, and 
dropped with increasing disease severity. The regression model significantly accounted for the variance in SF-6D scores 
(n = 1939; F [7,1931] = 120.05; p < 0.001; adjusted R-squared 0.3007), with TFC score, Behavioural score, and male gender 
significant predictors of SF-6D values (p < 0.001).
Conclusion To our knowledge, this is the first report of HSUVs for HD for countries other than the UK, and the first report 
of SF-6D HSUVs described for 12 European countries, according to demographic and clinical factors. Our analyses provide 
new insights into the relationships between HD disease characteristics and assessment of health-related quality of life in a 
form that can be used in policy-relevant economic evaluations.
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Background
Huntington’s Disease (HD) is a hereditary neurodegenera-
tive disorder which results in a number of motor, cogni-
tive, and psychiatric symptoms. The condition is character-
ised by involuntary movements, known as chorea, and an 
impairment of voluntary movements. Learning and memory 
problems, depression, obsessive compulsive disorder, and 
psychosis are frequently reported, as are personality and 
behaviour changes including apathy, irritability, impulsiv-
ity, and obsessionality [1].
HD onset usually occurs when individuals are in their 
forties, there are no therapies currently available that alter 
the disease course, and people with HD tend to live only 
10–20 years from diagnosis. The gene which causes HD 
is fully penetrant [2], and it has a devastating effect on an 
individual’s ability to walk, think, talk and reason [1]. In 
addition, individuals with HD have a 50% chance of pass-
ing the disease onto their children [3]. Diagnosis can have 
major implications which affect not only the person with 
HD, but also the rest of the family who may also be at risk 
of developing the disease [4].
The disorder is relatively uncommon. For example, in 
2012, a systematic review and meta-analysis estimated that 
there was an overall prevalence of adults with HD in Europe, 
North America, and Australia of 5.7 per 100,000 people [5]. 
Hence, despite its devastating impact on affected families, 
HD receives little attention at a national, or international, 
level. For example, the National Institute for Health and 
Care Excellence (NICE) [6], which provides guidelines for 
resource allocation regarding health and social care in the 
UK, makes no specific reference to the funding of treatments 
for people with HD.
The breadth of the personal, social, and economic impact 
of HD has, to date, been under-explored. Research by Busse 
et al. [7], utilising data from the European Huntington’s 
Disease Network (EHDN), has been fundamental to start-
ing to establish the health, social, and economic impacts 
of HD. This work has estimated the proportions of people 
with HD who use formal and informal care services, and has 
explored relationships between resource use, disease sever-
ity and functional ability. However, to date, no research is 
apparent which has reported the health-related quality of 
life (HRQoL) of people with HD in a manner that can be 
used in policy-relevant economic evaluations of treatments 
for the condition.
Health outcomes, in the context of health policy decision-
making, are frequently considered in the form of quality-
adjusted life-years (QALYs). QALYs combine quantity and 
quality of life in a single outcome measure, whereby length 
of life is adjusted by a weight representing the quality of 
life during that time. These quality weights, which are often 
referred to as health state utility values (HSUVs), can be 
estimated from preference-based measures [8]. Two of the 
most commonly used preference-based measures interna-
tionally are the EQ-5D [9] and the SF-6D [10].
We conducted a systematic review of HSUVs for HD. 
This identified just two relevant studies [11] [12]. Research 
by Hocaoglu et al. [11] focussed on exploring patient-proxy 
ratings of HRQoL at different stages of HD and investigated 
the factors which affect proxy ratings, whilst the study by 
Calvert et al. [12] considered the impact of rare long-term 
neurological conditions, including HD, on people’s HRQoL. 
Both studies were conducted in the UK and included sam-
ples of 105 and 53 people with HD, respectively. The EQ-5D 
was used in both studies and no breakdown was provided by 
demographic or clinical characteristics or disease staging. 
As such, very little is documented about HSUVs of people 
with HD.
Aims
The aims of this research were:
• to describe HSUVs for HD by demographic and clinical 
characteristics, using data from a European longitudinal, 
observational study;
• to compare HSUVs of people in the UK with HD with 
population norms;
• to identify the relative strength of demographic and clini-
cal characteristics in predicting HSUVs for HD.
Methods
Participants
Data from the European Huntington’s Disease Network 
REGISTRY study [13] were used for analysis. This is a 
multi-centre, multi-national, observational, longitudinal 
study of people with HD across Europe. Participants com-
plete a six-monthly battery of demographic, clinical, and 
patient-reported outcome measures, including gender, age, 
time since diagnosis, disease severity stage according to the 
Shoulson–Fahn Functional Capacity Rating Scale [14] and 
motor, cognitive, functional, and behavioural symptoms 
as rated by the United Huntington’s Disease Rating Scale 
(UHDRS) [15], and the SF-36. Participants enrolled in the 
REGISTRY study provide informed, written consent for 
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their anonymised data to be used for research purposes. All 
those who had provided initial data as of October 2014 were 
included in the following analyses.
Measures
United Huntington’s Disease Rating Scale (UHDRS) [15]
The UHDRS was developed as a clinical rating scale to 
assess four domains relating to the clinical features of HD 
and the course of the disease: motor function, cognitive 
function, behavioural difficulties, and functional capacity. 
The measure has undergone extensive reliability and valid-
ity testing and has been used as a primary outcome meas-
ure in a number of controlled clinical trials. The domains 
are scored separately, as follows.
Total Functional Capacity (TFC) This rates a person’s inde-
pendence, using Likert scales, in terms of five domains 
(occupation, ability to manage finances, ability to perform 
domestic chores, ability to perform personal activities of 
daily living, and setting for level of care). The score is the 
sum of Likert responses (0–3, or 0–2) to five items. Scores 
range from 0 to 13, with higher scores indicating higher 
functional capacity. A score of 13/13 is possible on the 
TFC. This corresponds to functional independence of an 
individual who has been diagnosed with HD, but has no 
symptoms.
Behavioural score This is the sum of Likert responses 
(scored 0–4) which rate the frequency and the severity 
of 11 behavioural symptoms (e.g., sad/mood, low self-
esteem/guilt, disruptive or aggressive behaviour, obses-
sions, hallucinations, and irritable behaviour). Scores 
can range from 0 to 88, with higher scores indicative of 
increased problems.
Cognition score This is the sum of raw scores (number of 
correct responses) to five cognitive tests. These are a pho-
nemic verbal fluency test (the Controlled Oral Word Asso-
ciation test [16], the Symbol Digit Modalities test [17], and 
three scores generated from the Stroop Color and Word tests 
[18]. Higher scores are indicative of better functioning.
Motor score This is the sum of Likert responses (scored 
0–4) to 31 motor symptoms items, e.g., ocular pursuit, max-
imal chorea, gait, and tongue protrusion). Scores range from 
0 to 124, with higher scores indicating greater impairment.
Shoulson–Fahn Functional Capacity Rating Scale [19]
The TFC score can be used to categorise people into five 
disease stages defined by the Shoulson–Fahn Functional 
Capacity Rating Scale. Stage I (earliest stage) includes 
scores 11–13, Stage II scores 7–10, Stage III scores 3–6, 
Stage IV scores 1–2, and Stage V score 0 (most advanced 
stage). Individuals in Stage I may be pre-manifest, i.e., they 
may have been diagnosed with the condition via genetic test-
ing, but have no clinical expression, Stage II can be charac-
terised by issues with work and some impairment with usual 
activities, Stage III may include problems with activities of 
daily living and the requirement for some care support, Stage 
IV indicates the need for assistance with most activities of 
daily living and 24 h care may be appropriate, and Stage V 
is indicative of requiring support with all activities of daily 
living and progression to the terminal phase of the condition.
Sf‑36/Sf‑6d [20]
The SF-36 includes 36 self-report questions which assess 
functional health and well-being from the patient’s perspec-
tive over the previous 4 weeks [20]. The measure is one of 
the most widely used tools worldwide for measuring patient-
reported outcomes. Participant responses to the SF-36 were 
converted to SF-6D values using the algorithm provided by 
Brazier et al. (2002). The SF-6D [10] is a preference-based 
measure of health, which provides health state utility values. 
Scores on the SF-6D can range from 0.3 to 1.0, where 0.3 
indicates the worst health state and 1.0 the best health state.
Data analyses
Mean (SD) SF-6D HSUVs were described by gender, age 
(under 35 years, 35–44 years, 45–54 years, 55–64 years, 
and 65 years and over), time since diagnosis (1–4 years, 
5–9 years, 10 years or more), and disease stage accord-
ing to the Shoulson–Fahn Functional Capacity Rating 
Scale (Stage I, Stage II, Stage III, and Stage IV/V). The 
values were described individually for the 12 European 
countries and across the countries as a whole. The SF-6D 
values from people with HD in the UK were compared 
with SF-6D norms for a representative sample of the UK 
population, reported by age [21].
A random-effects linear regression analysis was con-
ducted to estimate the relative strength of age, gender, 
time since diagnosis, and disease severity (according to the 
Total Functional Capacity score, and the UHDRS’s Motor 
score, Behavioural score, and Cognition score), in predict-
ing SF-6D values when respondents first provided data to 
the REGISTRY study. Standardized beta coefficients were 
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computed to directly compare the strength of prediction 
of each of the independent variables [beta coefficients are 
regression coefficients obtained by first standardising all 
variables to a mean of 0 and a standard deviation of 1]. A 
second regression analysis was conducted as above with 
the addition of country of residence as 12 binary inde-
pendent variables, i.e., resident of country X (0) or not 
resident of country X (1).
Multi-collinearity was assessed by checking correla-
tions between the independent variables, by use of the 
_rmdcoll in STATA, prior to inclusion in the regression 
analysis. The adequacy of the model fit was reviewed by 
examining a normality plot of residuals and a scatterplot of 
predicted values versus residual values. All analyses were 
conducted in Excel and STATA 12, and p values of less 
than 0.05 were considered to be statistically significant.
Table 1  SF-6D health state 
utility values by gender Mean Standard deviation Min Max Observations Individuals
All countries
 Female 0.695054 0.144963 0.3 1 5774 2836
 Male 0.707324 0.140701 0.3 1 5153 2549
Austria
 Female 0.752955 0.137642 0.35 1 88 51
 Male 0.783546 0.136137 0.42 1 110 58
France
 Female 0.647912 0.135184 0.3 1 795 360
 Male 0.666512 0.138597 0.3 1 691 324
Germany
 Female 0.695595 0.149368 0.3 1 1135 571
 Male 0.701092 0.134925 0.32 1 1026 497
Italy
 Female 0.675282 0.129783 0.3 1 248 161
 Male 0.700493 0.12746 0.32 1 223 146
Netherlands
 Female 0.71235 0.141317 0.3 1 532 245
 Male 0.704964 0.125869 0.41 1 415 182
Norway
 Female 0.726213 0.141851 0.36 1 272 73
 Male 0.767959 0.139001 0.39 1 245 85
Poland
 Female 0.696908 0.133193 0.32 1 705 363
 Male 0.686235 0.134987 0.3 1 595 315
Portugal
 Female 0.689557 0.156728 0.34 1 384 136
 Male 0.708045 0.156622 0.3 1 266 108
Spain
 Female 0.708491 0.150103 0.3 1 636 375
 Male 0.722517 0.153181 0.32 1 588 337
Sweden
 Female 0.745081 0.164067 0.33 1 124 52
 Male 0.725755 0.144714 0.33 1 139 54
Switzerland
 Female 0.722208 0.13359 0.35 1 77 35
 Male 0.699677 0.12578 0.43 0.96 93 37
UK
 Female 0.698362 0.142428 0.3 1 769 405
 Male 0.726599 0.136859 0.3 1 741 390
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Table 2  SF-6D health state 
utility values by age group Mean Standard deviation Min. Max. Observations Individuals
All countries
 Under 35 years 0.760387 0.139523 0.3 1 1811 1055
 35–44 years 0.717771 0.145022 0.3 1 2660 1451
 45–54 years 0.687817 0.138592 0.3 1 2822 1557
 55–64 years 0.674979 0.135299 0.3 1 2326 1211
 65 years and over 0.658051 0.136079 0.3 1 1308 700
Austria
 Under 35 years 0.811 0.102387 0.64 1 20 13
 35–44 years 0.809275 0.156283 0.35 1 69 34
 45–54 years 0.736078 0.136427 0.42 1 51 36
 55–64 years 0.756061 0.102681 0.53 1 33 17
 65 years and over 0.716 0.113284 0.51 0.93 25 16
France
 Under 35 years 0.730351 0.148846 0.36 1 171 86
 35–44 years 0.670348 0.13492 0.3 1 345 175
 45–54 years 0.641503 0.125873 0.3 1 386 205
 55–64 years 0.648115 0.133238 0.3 1 382 192
 65 years and over 0.615297 0.132804 0.34 1 202 113
Germany
 Under 35 years 0.774379 0.131078 0.38 1 338 203
 35–44 years 0.721186 0.148078 0.33 1 531 294
 45–54 years 0.692475 0.135764 0.3 1 602 339
 55–64 years 0.659823 0.126737 0.3 1 451 239
 65 years and over 0.626276 0.131203 0.32 1 239 112
Italy
 Under 35 years 0.695273 0.137354 0.38 1 55 46
 35–44 years 0.699573 0.131722 0.37 0.97 117 81
 45–54 years 0.669833 0.131667 0.32 1 120 84
 55–64 years 0.681226 0.110028 0.35 0.93 106 72
 65 years and over 0.69863 0.139695 0.3 1 73 43
Netherlands
 Under 35 years 0.739927 0.127738 0.39 1 137 75
 35–44 years 0.731773 0.148347 0.41 1 203 104
 45–54 years 0.704164 0.126814 0.32 1 269 142
 55–64 years 0.700437 0.128704 0.41 1 229 108
 65 years and over 0.658624 0.132249 0.3 0.97 109 59
Norway
 Under 35 years 0.766897 0.115017 0.55 1 58 26
 35–44 years 0.775417 0.142899 0.38 1 120 50
 45–54 years 0.731018 0.156396 0.36 1 167 59
 55–64 years 0.724952 0.146842 0.39 1 103 43
 65 years and over 0.744928 0.104031 0.51 1 69 23
Poland
 Under 35 years 0.740701 0.145356 0.3 1 385 217
 35–44 years 0.700069 0.128252 0.34 1 289 165
 45–54 years 0.66278 0.124237 0.32 0.96 259 147
 55–64 years 0.658906 0.120341 0.4 1 256 138
 65 years and over 0.646847 0.102877 0.38 0.96 111 67
Portugal
 Under 35 years 0.789608 0.143568 0.42 1 153 59
 35–44 years 0.691326 0.153885 0.37 1 181 73
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Results
Demographic and clinical characteristics
11,328 questionnaires were available from 5560 respondents 
with HD. Data were provided from more than 12 European 
countries, including 1510 responses from the UK. The mean 
(SD) age of respondents was 48.6 (13.3) years and 53% of 
the sample were female. The mean (SD) time since diagnosis 
was 4.5 (3.8) years.
Forty-six percent of the respondents were categorised as 
Stage I in terms of disease progression, 26% Stage II, 21% 
Stage III, and 7% Stage IV/V. The mean (SD) Total Func-
tional Capacity (TFC) score was 9.04 (3.82), the mean (SD) 
Behavioural score 12.76 (11.78), the mean (SD) Cognition 
score 187.49 (85.69), and mean (SD) motor score 29.06 
(23.33).
SF‑6D health state utility values according 
to demographic and clinical characteristics
Ten thousand nine hundred and twenty-seven unique SF-6D 
scores were available from respondents from all the coun-
tries that the REGISTRY includes, with 10,897 SF-6D 
HSUVs specific to 12 countries. Unadjusted HSUVs are 
described below and presented in Tables 1, 2, 3, and 4, 
Figs. 1 and 2.
Gender
HSUVs are presented in Table 1 by gender for the countries 
as a whole and for each of the 12 countries separately. The 
general pattern was for women to have lower SF-6D values 
than men.
Age
Table 2 and Fig. 1 present SF-6D values by age group. The 
data show a decline in values with age. The comparison of 
Table 2  (continued) Mean Standard deviation Min. Max. Observations Individuals
 45–54 years 0.662026 0.147543 0.36 1 153 69
 55–64 years 0.645833 0.133548 0.34 1 96 48
 65 years and over 0.655224 0.160022 0.3 0.96 67 32
Spain
 Under 35 years 0.794508 0.130217 0.33 1 244 177
 35–44 years 0.746099 0.144008 0.3 1 323 208
 45–54 years 0.687599 0.1457 0.34 1 279 180
 55–64 years 0.667126 0.153473 0.3 1 247 129
 65 years and over 0.640992 0.132989 0.38 1 131 86
Sweden
 Under 35 years 0.763571 0.142834 0.34 0.89 28 16
 35–44 years 0.762245 0.134788 0.54 1 49 22
 45–54 years 0.743253 0.154723 0.33 1 83 35
 55–64 years 0.719385 0.17946 0.33 1 65 27
 65 years and over 0.686579 0.128237 0.43 1 38 20
Switzerland
 Under 35 years 0.785517 0.119779 0.54 1 29 14
 35–44 years 0.691852 0.142452 0.45 0.93 27 17
 45–54 years 0.673778 0.116097 0.43 0.92 45 25
 55–64 years 0.681225 0.117874 0.35 0.93 49 19
 65 years and over 0.776 0.122018 0.54 0.93 20 8
UK
 Under 35 years 0.756667 0.146746 0.3 1 183 114
 35–44 years 0.714822 0.140459 0.35 1 394 219
 45–54 years 0.712357 0.138297 0.32 1 403 231
 55–64 years 0.702671 0.134274 0.3 1 307 177
 65 years and over 0.684036 0.13906 0.3 1 223 120
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Table 3  SF-6D health state 
utility values by time since 
diagnosis
Mean Standard deviation Min. Max. Observations Individuals
All countries
 Under 1 year 0.690792 0.14013 0.32 1 1401 1323
 1–4 years 0.683108 0.13482 0.3 1 3758 2255
 5–9 years 0.659088 0.13342 0.3 1 2346 1388
 10 years or more 0.639765 0.12777 0.3 1 767 449
Austria
 Under 1 year 0.744286 0.14587 0.35 1 28 28
 1–4 years 0.786868 0.12872 0.4 1 83 51
 5–9 years 0.746444 0.12619 0.49 1 45 30
 10 years or more 0.653636 0.11281 0.49 0.8 11 10
France
 Under 1 year 0.665258 0.12956 0.36 1 194 184
 1–4 years 0.652803 0.12739 0.3 1 610 355
 5–9 years 0.622319 0.13019 0.3 1 401 233
 10 years or more 0.571809 0.09988 0.3 0.85 94 55
Germany
 Under 1 year 0.684045 0.14096 0.32 1 267 255
 1–4 years 0.676967 0.12866 0.32 1 755 464
 5–9 years 0.659446 0.13117 0.3 1 469 297
 10 years or more 0.649392 0.14043 0.3 1 181 108
Italy
 Under 1 year 0.683171 0.12795 0.37 1 82 78
 1–4 years 0.696809 0.12584 0.32 1 188 134
 5–9 years 0.652072 0.12413 0.35 0.97 111 78
 10 years or more 0.647407 0.15934 0.3 1 27 18
Netherlands
 Under 1 year 0.701318 0.13212 0.32 1 129 120
 1–4 years 0.691862 0.12623 0.3 1 333 197
 5–9 years 0.667908 0.11375 0.36 1 196 111
 10 years or more 0.65 0.10821 0.41 1 60 36
Norway
 Under 1 year 0.731404 0.14487 0.41 1 57 53
 1–4 years 0.740581 0.13607 0.38 1 172 79
 5–9 years 0.712447 0.14251 0.38 1 94 40
 10 years or more 0.701892 0.10173 0.56 1 37 13
Poland
 Under 1 year 0.68426 0.126 0.38 1 277 263
 1–4 years 0.664209 0.12526 0.32 1 449 267
 5–9 years 0.649503 0.11622 0.38 0.97 201 113
 10 years or more 0.624286 0.09676 0.4 0.93 49 28
Portugal
 Under 1 year 0.660678 0.1595 0.36 1 59 53
 1–4 years 0.670094 0.15398 0.3 1 213 114
 5–9 years 0.631615 0.14723 0.34 1 130 70
 10 years or more 0.618438 0.13716 0.36 1 32 16
Spain
 Under 1 year 0.691752 0.15795 0.33 1 137 130
 1–4 years 0.683433 0.14167 0.38 1 300 210
 5–9 years 0.657255 0.13866 0.3 1 255 147
 10 years or more 0.608317 0.12365 0.32 0.89 101 61
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SF-6D values by age for people with HD in the UK with 
values from a representative sample of the UK general 
population shows SF-6D values of people with HD to be 
consistently lower than those without the condition in all 
age groups.
Time since diagnosis
Table 3 shows a negligible drop in values, as time since 
diagnosis increases.
Disease stage
Table 4 and Fig. 2 indicate that SF-6D values decrease as 
HD progresses, with the most substantial drop between 
Stage I and Stage II, both for all the countries combined 
and the UK separately.
Strength of demographic and clinical characteristics 
in predicting HSUVs
Checks for multi-collinearity indicated that it was appro-
priate to include all independent variables in the regres-
sion model, and examination of normality plots of the 
regression residuals and scatterplots of predicted SF-6D 
and residual values also indicated the appropriateness of 
this analysis (Appendices 1 and 2).
Table 5 presents the results of the regression analy-
sis. The model significantly accounted for the variance in 
SF-6D scores (n = 1939; F [7,1931] = 120.05; p < 0.001; 
adjusted R-squared 0.3007). TFC score, Behavioural score, 
and male gender were significant predictors of SF-6D 
values (all at p < 0.001). The regression results for these 
variables indicated the following:
 (i) The coefficient estimated for the TFC variable was 
0.009, indicating that an one point change in the TFC 
score (range 0–13) corresponded to a 0.009 change in 
SF-6D score. For example, a decline in independence 
for a person with HD from a position of functional 
independence with a TFC score of 13 (Stage I on 
the TFC scale) to a state of total dependence with 
a TFC score of 0 (Stage V on the TFC scale) has, 
on average, a corresponding decrease of 0.119 in 
their HSUV (i.e., a change of 13 points on the TFC 
scale equates to a decrease of 0.119 on the SF-6D 
[13*0.0091764]).
 (ii) The coefficient for Behavioural score was 0.005, 
indicating that an increase in behavioural difficul-
ties by one point corresponds to a drop in SF-6D 
score of 0.005. This equates, for example, to an aver-
age drop in SF-6D value of 0.416 from having no 
behavioural difficulties (score of 0) to having the 
maximum score on the Behavioural scale (score 
of 88) [88*− 0.0047258]. Given that a minimally 
important difference of 0.041 on the SF-6D has been 
reported [22], these drops in SF-6D scores in line 
with increased behavioural difficulties appear to have 
distinct clinical relevance.
 (iii) On average, men have SF-6D values 0.019 points 
higher than women.
The beta weights for the independent variables (given 
in Table 5) show the relative strength of each of these as 
predictors of SF-6D values. By far, the strongest predic-
tor was the frequency and severity of behaviour problems 
Table 3  (continued) Mean Standard deviation Min. Max. Observations Individuals
Sweden
 Under 1 year 0.690556 0.14293 0.46 0.93 18 17
 1–4 years 0.733111 0.16335 0.34 1 90 48
 5–9 years 0.707778 0.16237 0.33 1 81 39
 10 years or more 0.695833 0.18923 0.33 1 12 7
Switzerland
 Under 1 year 0.764 0.11673 0.58 0.89 10 10
 1–4 years 0.698269 0.1462 0.35 0.96 52 27
 5–9 years 0.676216 0.10782 0.45 0.85 37 23
 10 years or more 0.650526 0.1025 0.48 0.92 19 9
UK
 Under 1 year 0.725315 0.15276 0.36 1 143 132
 1–4 years 0.692854 0.13305 0.35 1 508 305
 5–9 years 0.677901 0.13128 0.3 1 324 205
 10 years or more 0.675278 0.12062 0.32 0.92 144 88
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Table 4  SF-6D health state 
utility values by disease stage Mean Standard deviation Min Max Observations Individuals
All countries
 Stage I 0.766802 0.131412 0.3 1 4991 2869
 Stage II 0.674682 0.128271 0.3 1 2753 1755
 Stage III 0.632616 0.120776 0.3 1 2282 1500
 Stage IV or V 0.574574 0.117588 0.3 1 774 571
Austria
 Stage I 0.84662 0.106234 0.57 1 71 43
 Stage II 0.794889 0.116163 0.52 1 45 32
 Stage III 0.683878 0.124697 0.35 0.96 49 35
 Stage IV or V 0.676957 0.137459 0.42 1 23 17
France
 Stage I 0.727054 0.12818 0.41 1 577 305
 Stage II 0.647201 0.123765 0.36 1 393 246
 Stage III 0.59593 0.113446 0.3 1 398 264
 Stage IV or V 0.544159 0.113143 0.3 1 113 93
Germany
 Stage I 0.762888 0.132533 0.38 1 987 588
 Stage II 0.683287 0.126591 0.3 1 505 328
 Stage III 0.625195 0.115707 0.32 0.96 435 290
 Stage IV or V 0.556803 0.109825 0.3 0.95 147 116
Italy
 Stage I 0.73257 0.119209 0.49 1 214 158
 Stage II 0.684516 0.123902 0.33 1 124 93
 Stage III 0.629579 0.108911 0.32 0.97 95 79
 Stage IV or V 0.582162 0.134001 0.3 0.85 37 32
Netherlands
 Stage I 0.772891 0.130058 0.44 1 422 231
 Stage II 0.674352 0.107185 0.36 1 239 152
 Stage III 0.656305 0.124521 0.3 1 203 128
 Stage IV or V 0.606986 0.10237 0.36 0.96 73 49
Norway
 Stage I 0.788699 0.135195 0.38 1 269 99
 Stage II 0.716343 0.141254 0.36 1 134 66
 Stage III 0.695222 0.1221 0.38 0.96 90 43
 Stage IV or V 0.626522 0.117922 0.39 0.88 23 17
Poland
 Stage I 0.758336 0.127962 0.4 1 607 367
 Stage II 0.651849 0.113278 0.39 0.97 357 231
 Stage III 0.625165 0.102667 0.3 0.96 273 171
 Stage IV or V 0.56459 0.090306 0.38 0.76 61 40
Portugal
 Stage I 0.754729 0.139255 0.36 1 387 153
 Stage II 0.637239 0.136918 0.38 1 134 78
 Stage III 0.588081 0.131201 0.3 1 99 61
 Stage IV or V 0.48579 0.123257 0.34 0.8 19 15
Spain
 Stage I 0.786346 0.133099 0.3 1 665 442
 Stage II 0.658841 0.126674 0.33 1 207 150
 Stage III 0.640556 0.119292 0.3 0.97 198 139
 Stage IV or V 0.565308 0.117455 0.32 0.96 130 77
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(Behavioural score, β = − 0.405), followed by the degree 
of functional independence (TFC score, β = 0.233). The 
next strongest predictor of higher HSUVs was male gen-
der (β = 0.069), with the other predictors having relatively 
negligible effects. The results of the regression analysis 
including country of residence are shown in Appendix 3.
Discussion
To our knowledge, this is the first report of HSUVs for HD 
for countries other than the UK, and the first report of SF-6D 
values described individually for 12 European countries, 
broken down by demographic and clinical factors.
Our descriptive analysis indicated that women with HD 
generally had lower SF-6D HSUVs than men, and this find-
ing held when gender was included in a regression analysis 
Table 4  (continued) Mean Standard deviation Min Max Observations Individuals
Sweden
 Stage I 0.788807 0.124229 0.51 1 109 56
 Stage II 0.730538 0.156486 0.43 1 93 40
 Stage III 0.667805 0.163623 0.33 1 41 30
 Stage IV or V 0.586875 0.128152 0.33 0.77 16 10
Switzerland
 Stage I 0.777024 0.11373 0.45 1 84 43
 Stage II 0.661667 0.107504 0.43 0.85 36 21
 Stage III 0.648438 0.118624 0.35 0.96 32 21
 Stage IV or V 0.601765 0.089109 0.45 0.76 17 15
UK
 Stage I 0.789353 0.123431 0.39 1 541 332
 Stage II 0.689479 0.130967 0.35 1 461 296
 Stage III 0.655718 0.121061 0.3 1 348 222
 Stage IV or V 0.603048 0.120736 0.3 0.96 105 81
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which controlled for other demographic and clinical vari-
ables. Although the descriptive data indicated a decline in 
HSUVs by age group, age was not statistically significantly 
associated with SF-6D values when other characteristics 
were controlled for. HSUVs declined by disease stage, with 
the most substantial drop between Stages I and II. This may 
be indicative of the fact that some individuals are diag-
nosed in the pre-manifest stage because of family history 
of the condition and early predictive testing, and experience 
no symptoms in Stage I [14]. This may also explain why 
there was not a statistically significant relationship between 
HSUVs and time since diagnosis, as some individuals may 
be diagnosed with HD and live for decades without any clin-
ical expression, whilst others may only be diagnosed at the 
point of experiencing significant symptomatology.
The regression analysis indicated a significant asso-
ciation between HSUVs and behavioural symptoms, e.g., 
sadness/low mood, low self-esteem/guilt, disruptive or 
aggressive behaviour, obsessions, hallucinations, and irri-
table behaviour. This relationship was more substantial than 
the relationship between disease severity (as assessed by 
functional independence) and HSUVs, suggestive of the key 
role that such behavioural symptoms may play in HRQoL. 
Our analyses indicate the importance of these behavioural 
symptoms in the context of much less significant relation-
ships between cognitive symptoms and HSUVs and motor 
symptoms and HSUVs, and reflect that although the clinical 
diagnosis of HD is based on the presence of the movement 
disorder, behavioural changes appear to be the most debili-
tating aspect of the condition [14]. People with HD are eight 
times more likely to commit suicide than other members 
of the general population [23], with HD fracturing lives of 
entire families: economically, socially, and emotionally. The 
impacts of HD appear far-reaching with a reported increased 
prevalence of criminal behaviour in males who carry the 
gene, and the suggestion that this criminal behaviour is prob-
ably linked to the personality changes exhibited as a result 
of the condition, or related to the depressive reactions to the 
illness coupled with secondary alcohol misuse [24].
The size and coverage of the European Huntington’s Dis-
ease Network REGISTRY study data set has been a major 
asset for this research. It has enabled us to analyse HSUVs 
by key demographic variables and clinical factors pertinent 
to the condition across 12 European countries. Clearly, our 
results are constrained by the particular measures used in the 
REGISTRY study. The finding that behavioural symptoms 
were so strongly related to HSUVs, and cognitive and motor 
symptoms were not, may be indicative of the instruments 
used to assess these areas of functioning. However, each of 
these measures forms part of the United Huntington’s Dis-
ease Rating Scale (UHDRS) [15], the main internationally 
recognised tool for assessing the symptoms of HD.
The ongoing, longitudinal data collection of the REGIS-
TRY study provides a unique opportunity for future research 
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0.69
0.66
0.6
0.3
0.4
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0.6
0.7
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0.9
1
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HD stageAll countries UK
Fig. 2  Mean SF-6D health state utility values by disease stage
Table 5  Results of random-effects GLS regression to explore relationships between demographic and clinical variables and SF-6D health state 
utility values
n = 1939; F [7,1931] = 120.05; p < 0.001; Adjusted R-squared 0.3007
a Beta coefficients were obtained by standardising all variables to a mean of 0 and a standard deviation of 1, and then including them in the 
regression analysis
SF-6D value Coefficient Standard error p > z Lower confidence 
interval
Upper confidence 
interval
Beta  coefficientsa
TFC score 0.0091764 0.0011486 0.0000000 0.0069239 0.0114290 0.2328026
Behavioural score − 0.0047258 0.0002288 0.0000000 − 0.0051744 − 0.0042771 − 0.4053759
Cognition score 0.0000891 0.0000596 0.1350000 − 0.0000278 0.0002060 0.0430957
MOT score − 0.0002756 0.0002094 0.1880000 − 0.0006862 0.0001350 − 0.0384748
Male gender 0.0188754 0.0052631 0.0000000 0.0085535 0.0291973 0.0686814
Age − 0.0002946 0.0002174 0.1760000 − 0.0007210 0.0001318 − 0.0270106
Years since diagnosis 0.0014575 0.0008332 0.0800000 − 0.0001766 0.0030917 0.0375215
Constant 0.6527599 0.0233794 0.0000000 0.6069084 0.6986114
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to consider the responsiveness of the SF-6D for people with 
HD over time, and in relation to treatments that are currently 
in development. Further research may also usefully explore 
the comparative responsiveness of the SF-6D and the EQ-5D 
to health-related changes in the lives of people with HD. The 
EQ-5D is the most common internationally used preference-
based measure for estimating QALYs, and is recommended 
for use by the UK’s National Institute of Health and Care 
Excellence in health and social care policy decision-making 
[25]. It would be of value to determine whether changes in 
the HRQoL of people with HD are more/less likely to be 
detected by each of these economic evaluation measures, 
particularly given that the SF-6D provides higher HSUVs 
than the EQ-5D because the values are estimated using the 
standard gamble technique and respondents tend to be risk 
averse. This is evidenced here as our study found females 
with HD resident in the UK to have a mean (SD) SF-6D 
score of 0.698 (0.142), whilst males had a mean (SD) score 
of 0.727 (0.137). In comparison, the two previous studies 
that included HSUVs of people with HD, both conducted in 
the UK, reported EQ-5D scores of a mean (standard devia-
tion) of 0.56 (0.35) [range − 0.33 to 1] [11] and a mean 
(95% confidence interval) of 0.30 (0.19, 0.41) [12]. Thus, the 
SF-6D may demonstrate lower health gains relative to esti-
mates based on the EQ-5D. The development of the inter-
national Enroll-HD platform [26] may provide additional 
opportunities to address some of these issues.
In conclusion, this research has provided new empiri-
cal data on the health state utility values associated with 
Huntington’s disease, in a format that can inform the cost-
effectiveness analyses of treatments for people with HD. The 
provision of this information, based on assessments across 
a number of European countries, can aid health policy deci-
sion makers, clinicians, and people with HD.
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